Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Akshaya Bio
Edmonton, Alberta, Canadaakshayabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Akshaya Bio’s Chimigen technology enables the creation of a new class of therapeutic vaccines and agents targeting both infectious diseases and cancer. The platform mimics natural immune processes and claims improved antigen presentation and safety (no adjuvant required). Product pipeline includes candidates for hepatitis B and C, HIV, influenza, malaria, cancer, TB, and Ebola, but clinical results have not been published.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineBiologicAntibody
- Industry
- Biotech
Beyond the preview
Go deeper on Akshaya Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akshaya Bio.